, Ordre des médecins. Relation médecin

C. Bauters, Prognosis of Patients With Stable Coronary Artery Disease (from the CORONOR Study), Am J Cardiol, vol.113, pp.1142-1145, 2014.

J. J. Goldberger, R. O. Bonow, M. Cuffe, L. Liu, Y. Rosenberg et al., Effect of Beta-Blocker Dose on Survival After Acute Myocardial Infarction, J Am Coll Cardiol, vol.66, issue.13, pp.1431-1472, 2015.

C. Andersson, D. Shilane, A. S. Go, T. I. Chang, D. Kazi et al., BetaBlocker Therapy and Cardiac Events Among Patients With Newly Diagnosed Coronary Heart Disease, J Am Coll Cardiol, vol.64, issue.3, pp.247-52, 2014.

S. Bangalore, G. Steg, P. Deedwania, K. Crowley, K. A. Eagle et al., ?-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease, JAMA, vol.308, issue.13, pp.1340-1349, 2012.

C. Baigent, L. Blackwell, R. Collins, J. Emberson, and J. Godwin, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Antithrombotic Trialists' (ATT) Collaboration, vol.373, pp.1849-60, 2009.

S. R. Mehta and S. Yusuf, Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study Investigators. The Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) trial programme; rationale, design and baseline characteristics including a meta-analysis of the effects of thienopyridines in vascular disease, Eur Heart J, vol.21, issue.24, pp.2033-2074, 2000.

L. Wallentin, R. C. Becker, A. Budaj, C. P. Cannon, H. Emanuelsson et al., Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes

.. J. Engl and . Med, , vol.361, pp.1045-1057, 2009.

G. Montalescot, S. D. Wiviott, E. Braunwald, S. A. Murphy, C. M. Gibson et al., Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial, Lancet Lond Engl, vol.373, issue.9665, pp.723-754, 2009.

C. P. Cannon, E. Braunwald, C. H. Mccabe, D. J. Rader, J. L. Rouleau et al., Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes, N Engl J Med, vol.350, issue.15, pp.1495-504, 2004.

V. Durand and D. , Statines : des informations disponibles à la prescription courante, vol.35, pp.151-154, 2014.

, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet Lond Engl, vol.344, issue.8934, pp.1383-1392, 1994.

, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet Lond Engl, vol.360, issue.9326, pp.7-22, 2002.

. Long-term, Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, vol.339, pp.1349-57, 2019.

J. Shepherd, S. M. Cobbe, I. Ford, C. G. Isles, A. R. Lorimer et al., Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia, N Engl J Med, vol.333, issue.20, pp.1301-1309, 1995.

B. Ibanez, S. James, S. Agewall, M. J. Antunes, C. Bucciarelli-ducci et al., ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationThe Task Force for the management of acute myocardial infarction in patients presenting with STsegment elevation of the European Society of Cardiology (ESC), Eur Heart J, vol.00, pp.1-66, 2017.

F. M. Sacks, M. A. Pfeffer, L. A. Moye, J. L. Rouleau, J. D. Rutherford et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels

, N Engl J Med, vol.335, issue.14, pp.1001-1010, 1996.

, HAS. Guide du parcours de soin maladie coronarienne stable

G. R. Dagenais, J. Pogue, K. Fox, M. L. Simoons, and S. Yusuf, Angiotensin-convertingenzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials, Lancet Lond Engl, vol.368, issue.9535, pp.581-589, 2006.

S. Yusuf, P. Sleight, J. Pogue, J. Bosch, and R. Davies, Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, Heart Outcomes Prevention Evaluation Study Investigators, vol.342, pp.145-53, 200020.

, Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). The Lancet, vol.362, pp.782-790, 2003.

E. Braunwald, M. J. Domanski, S. E. Fowler, N. L. Geller, B. J. Gersh et al.,

, Angiotensin-converting-enzyme inhibition in stable coronary artery disease

J. Engl and . Med, , vol.351, pp.2058-68, 2004.

P. Even and B. Debré, Guide des 4000 médicaments utiles, inutiles ou dangereux. Le cherche midi, 2012.

P. G. Steg, One-year cardiovascular event rates in outpatients with atherothrombosis, JAMA, vol.297, pp.1197-206, 2007.

G. W. Stone, A prospective natural-history study of coronary atherosclerosis, N Engl J Med, vol.364, issue.3, p.38, 2011.

A. Astier, F. Blanchet, A. Brouard, P. Y. Chambrin, and J. L. Delmas, Rapport de l'académie de pharmacie. Observance des traitements médicamenteux en France, 2015.

M. M. Fulton and E. R. Et-allen, Polypharmacy in the elderly: a literature review, J Am Acad.Nurse ? Pract, vol.17, issue.4, pp.123-132, 2005.

E. R. Hajjar, A. C. Cafiero, and J. T. Et-hanlon, Polypharmacy in elderly patients, Am J Geriatr. Pharmacother, vol.5, issue.4, pp.345-351, 2007.

M. Monégat, C. Sermet, and M. Perronnin, «La polymédication : définitions, mesures et enjeux Revue de la littérature et tests de mesure», 2014.

A. Aouba, M. Eb, G. Rey, G. Pavillon, and E. Jougla, Données sur la mortalité en France : principales causes de décès en 2008 et évolutions depuis, Bull Epidémiol Hebd, issue.22, pp.249-55, 2000.

C. Droz, C. Dureau, D. Thomas, N. Danchin, J. Tricoire et al., , vol.17, p.476, 2014.

P. Tuppin, A. Neumann, N. Danchin, A. Weill, P. Ricordeau et al.,

, Chaînage des données du PMSI avec les données de remboursement de l'assurance-maladie : exemple de l'analyse de la prévention secondaire après un infarctus du myocarde. Rev DÉpidémiologie Santé Publique, vol.57, p.87, 2009.

, Actes et prestations. Affections de longue durée. HAS, 2016.

, Haute Autorité de Santé Bonnes pratiques et criteres de qualite des revues et journaux de la presse medicale francaise. HAS, 2013.

C. De-peretti, F. Chin, P. Tuppin, and D. Danchin, Personnes hospitalisées pour infarctus du myocarde en France : tendances, Bull Epidémiol Hebd, issue.41, pp.459-65, 2002.

N. Danchin, La maladie coronaire, session commune caisse nationale d'assurance maladie/SFC : les bases de données de l'assurance maladie : une mine d'or ? », congres SFC, vol.16, 2014.

R. Labonté and C. Desbordes, Rien n'est permanent sauf le changement

L. Osterberg and T. Blaschke, Adherence to medication, N Engl J Med, vol.353, pp.487-497, 2005.

D. M. Cutler and W. Everett, Thinking outside the pillbox -Medication adherence as a priority for health care reform, N Engl J Med, vol.362, pp.1553-1555, 2010.

C. Cahir, T. Fahey, M. Teeling, C. Teljeur, J. Feely et al., Potentially inappropriate prescribing and cost outcomes for older people: a national population study, Br J Clin Pharmacol?, vol.69, issue.5, pp.543-552, 2010.

M. Biencourt and P. Bouet, Rapport de la Commission nationale permanente adopté lors des Assises du Conseil national de l'Ordre des médecins du 19 juin, 2010.

L. Guize, D. Thomas, N. Danchin, F. Paillard, J. Tricoire et al.,

, Cohorte EOLE en post-infarctus du myocarde : impact de la non-réponse aux questionnaires de suivi attendus sur le risque de mortalité à 6 ans, p.8

, Colloque Données de Santé en vie réelle, 2016.

M. S. Sabatine, R. P. Giugliano, A. C. Keech, N. Honarpour, S. D. Wiviott et al., Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
URL : https://hal.archives-ouvertes.fr/hal-01896445

, N Engl J Med, vol.376, issue.18, pp.1713-1735, 201704.

T. Jernberg, P. Hasvold, and M. Henriksson, Cardiovascular risk in postmyocardial infarction patients: nationwide real world data demonstrate the ! 40 importance of a long-term perspective, Eur Heart J, vol.14, issue.19, pp.31357-31362, 2015.

J. Bezin, F. Francis, and N. V. Nguyen, Impact of a public media event on the use of statins in the French population, Archives of Cardiovascular Diseases

A. Saiba, L. Sabbah, L. Perdrixa, D. Blancharda, N. Danchin et al., Evaluation of the impact of the recentcontroversy over statins in France: The EVANS study Évaluation de l'impact de la controverse récente sur les statines en France. Archives of cardiovascular Disease, 2013.

J. Barbot and N. Dodier, L'émergence d'un tiers public dans la relation médecin-malade: exemple du VIH. Science sociale et santé. 2000 mars, pp.76-119